Nutra Pharma (Nutra Pharma) Quality Rank

View and export this data going back to . Start your Free Trial

What is Nutra Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Nutra Pharma Quality Rank Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutra Pharma (Nutra Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1537 NW 65th Avenue, Plantation, FL, USA, 33313

Website

https://www.nutrapharma.com

Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.

Executives

Rik J Deitsch	officer: Chief Executive Officer	4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran	director	8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori	other: Former CFO	275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph	director, officer: President - ReceptoPharm	1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman	officer: Chief Marketing Officer	2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck	director	10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid	director	9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty	director, officer: Executive Chairman
Tanvir A Khandaker	director	387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky	director	1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein	director	2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax	director, officer: Chief Financial Officer	2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr	director	P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder	director	PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md	director	436 N BEDFORD DR, BEVERLY HILLS CA 90210